https://www.businesswire.com/news/home/20230822149790/en/Vistagen-Appoints-Cindy-Anderson-as-Chief-Financial-Officer
Vistagen Appoints Cindy Anderson as Chief Financial Officer
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depr...
appointscindyandersonchieffinancial
https://secure.businesswire.com/news/home/20250807014578/en/Vistagen-Reports-Fiscal-Year-2026-First-Quarter-Financial-Results-and-Corporate-Update
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerciali...
fiscal yearfirst quarter
https://www.businesswire.com/news/home/20260303528278/en/Vistagen-to-Participate-in-Upcoming-Investor-Conferences
Vistagen to Participate in Upcoming Investor Conferences
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerciali...
to participateupcominginvestorconferences
https://www.businesswire.com/news/home/20230330005332/en/FDA-Provides-Positive-Feedback-to-Vistagen-Regarding-Use-of-the-Liebowitz-Social-Anxiety-Scale-LSAS-as-an-Endpoint-in-Phase-3-Development-of-Fasedienol-PH94B-for-Treatment-of-Social-Anxiety-Disorder
FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, dep...
https://www.businesswire.com/news/home/20260212959012/en/Vistagen-Reports-Fiscal-Year-2026-Third-Quarter-Financial-Results-and-Provides-Corporate-Update
Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerciali...
https://www.businesswire.com/news/home/20230124005493/en/Vistagen-Announces-First-Participants-Dosed-in-Phase-1-Clinical-Trial-of-PH10-an-Investigational-Pherine-Nasal-Spray-for-Major-Depressive-Disorder
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational...
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depr...